Neuropace INC Form 4 insider transactions

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has sold a portion of its holdings in a series of transactions between May 1st and May 3rd, 2024.

OrbiMed Advisors LLC reports the sale of 1,781 shares of NeuroPace Inc (NPCE) at $14.06 per share on April 24, 2024, while still indirectly holding a significant number of shares.

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has reported the sale of common stock in a series of transactions between April 19 and April 23, 2024.

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has sold a portion of its common stock holdings in a series of transactions between April 16 and April 18, 2024.

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has sold a portion of its common stock holdings in two transactions on April 11 and 12, 2024.

Chief Medical Officer Martha Morrell reports acquiring 12,500 shares of common stock and 24,950 stock options in NeuroPace Inc.

NeuroPace's Chief Financial Officer, Rebecca Kuhn, reported the acquisition of 12,500 shares of common stock and 24,950 stock options.

NeuroPace's CEO, Joel Becker, reports the acquisition of stock options and restricted stock units (RSUs) in the company.